Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Finished Goods (2016 - 2018)

Lifecore Biomedical, Inc. \De\ has reported Finished Goods over the past 7 years, most recently at $13.9 million for Q4 2018.

  • Quarterly results put Finished Goods at $13.9 million for Q4 2018, up 7.93% from a year ago — trailing twelve months through Nov 2018 was $13.9 million (up 7.93% YoY), and the annual figure for FY2018 was $12.9 million, up 28.42%.
  • Finished Goods for Q4 2018 was $13.9 million at Lifecore Biomedical, Inc. \De\, up from $12.9 million in the prior quarter.
  • Over the last five years, Finished Goods for LFCR hit a ceiling of $17.1 million in Q3 2016 and a floor of $10.0 million in Q2 2017.
  • Median Finished Goods over the past 5 years was $12.8 million (2016), compared with a mean of $12.7 million.
  • Biggest five-year swings in Finished Goods: dropped 26.16% in 2017 and later rose 28.42% in 2018.
  • Lifecore Biomedical, Inc. \De\'s Finished Goods stood at $14.3 million in 2014, then decreased by 0.81% to $14.2 million in 2015, then fell by 24.33% to $10.7 million in 2016, then increased by 20.2% to $12.9 million in 2017, then grew by 7.93% to $13.9 million in 2018.
  • The last three reported values for Finished Goods were $13.9 million (Q4 2018), $12.9 million (Q3 2018), and $12.9 million (Q2 2018) per Business Quant data.